

Stock Code: 603707 Stock Abbreviation: Jianyou Stock **Announcement Number: 2023-058**

Bond code: 113579 Bond abbreviation: Jianyou convertible bond

Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.

About the subsidiary product Plerixafor Injection

Announcement of US FDA approval

The company's board of directors, all directors and relevant shareholders guarantee that there are no false records, Misleading statements or major omissions, and individually and jointly responsible for the authenticity, accuracy and completeness of its contents

Take responsibility.

Jianyou, a subsidiary of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianyou shares" or the "Company")

Jin Jin Pharmaceutical Co., Ltd. (hereinafter referred to as "Jin Jin Pharmaceutical") has recently received the US Food and Drug Administration (referred to as

Plerixafor injection, 24 mg/1.2 mL (20 mg/mL), single dose

The ANDA Final Approval Notice (ANDA No.: 215698), the relevant information is hereby announced as follows:

1. Basic information of medicines

(1) Drug name: Plerixafor Injection

(2) Indications: combined with granulocyte colony-stimulating factor (G-CSF), suitable for non-Hodgkin lymphoma

Patients with tumors or multiple myeloma mobilize hematopoietic stem cells (HSCs) into peripheral blood in order to complete HSC collection

Set with autograft.

(3) Dosage Form: Injection

(4) Specification: 24 mg/1.2 mL (20 mg/mL)

(5) ANDA No.: 215698

(6) Applicant: Jianjin Pharmaceutical Co., Ltd.

2. Other related information about drugs

Plerixafor injection, 24 mg/1.2 mL (20

mg/mL) ANDA application was tentatively approved on December 15, 2022. July 24, 2023

The product received final approval from the US FDA.

Plerixafor injection, 24 mg/1.2 mL (20 mg/mL), the reference preparation is GENZYME CORP

Hold, on December 15, 2008 was approved by the US FDA for marketing.

After inquiry, the United States currently has AMNEAL EU LTD, DR REDDYS LABORATORIES LTD, EUGIA PHARMA SPECIALITIES LTD, MSN LABORATORIES PRIVATE

LTD, TEVA PHARMACEUTICALS USA INC and Gengen Pharmaceuticals Co., Ltd. 6 Plerixafor

Injection, 24 mg/1.2 mL (20 mg/mL) generic drug approved for marketing, the product will be sold in the US market in 2022

Sales were approximately \$192 million.

Up to now, the company has completed the R&D project of Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL)

The investment in research and development is approximately RMB 6,243,900.

3. Impact on the company

The newly approved products will be launched in the United States in the near future, which is expected to have a positive impact on the company's operating performance.

4. Risk warning

The company attaches great importance to drug research and development, and strictly controls the quality and safety of drug research and development, production and sales.

However, the production and sales of products are easily affected by uncertain factors such as national policies and market environment, and there may be

When sales fall short of expectations, etc. Investors are advised to make decisions carefully and pay attention to guard against investment risks.

Special announcement.

Board of Directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.

July 26, 2023